Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration, but each potentially has severe adverse events.
Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.
Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs will provide cardiologists with information about the etiology of anemia in CKD, the effects on CV disease, HRQOL, and function, advantages and limitations of current management strategies, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.
At the conclusion of this activity, participants should be able to:
- Discuss the etiology of anemia in chronic kidney disease
- Summarize how anemia affects functioning, quality of life, and health outcomes, for patients with cardiovascular disease and chronic kidney disease
- Assess the benefits and limitations of available modalities for treating anemia in chronic kidney disease
- Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease
Erin Michos, MD, MHS
Associate Professor of Medicine
Division of Cardiology
Johns Hopkins School of Medicine
Matthew Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Jointly provided by USFH and Rockpointe.
This educational activity is supported by an educational grant from GlaxoSmithKline.